Pulmonary artery pressure trajectories in heart failure patients treated with GLP‐1 receptor agonists DOI Creative Commons
Haoran Jiang, Phuuwadith Wattanachayakul, Veraprapas Kittipibul

и другие.

ESC Heart Failure, Год журнала: 2025, Номер unknown

Опубликована: Апрель 27, 2025

Abstract Aims Data support favourable haemodynamic benefits of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) on improving cardiac structural abnormalities and function in patients with heart failure (HF). However, the direct effects GLP‐1 RAs remain inadequately characterized. We aim to investigate temporal trends pulmonary artery pressure (PAP) HF receiving RAs. Methods results In this single‐centre retrospective cohort study, we identified a CardioMEMS device who received semaglutide or tirzepatide for at least 6 months during monitoring period. Patients were already prior implantation excluded. The relationship between weight change PAPs was assessed using Pearson correlation. A total nine included (54 years, BMI 41.4 kg/m 2 , 67% men, 44% EF < 40%, 89% diabetes, semaglutide). Median dose (or equivalent) 0.9 (range 0.25–1) mg/week. Body significantly decreased from 123.6 117.2 kg ( P = 0.047), while guideline‐directed medical therapy (GDMT) loop diuretic uses dosages remained unchanged. Significant reductions observed systolic PAP (38.9 34.0 mmHg, 0.045), diastolic (20.0 17.8 0.019) mean (27.3 24.3 0.018). There significant correlation loss r 0.69, 0.04) 0.72, 0.029). Conclusions GLP1‐RA use associated body months, despite no changes GDMT doses.

Язык: Английский

Glucagon-like peptide-1 receptor modulates cerebrospinal fluid secretion and intracranial pressure in rats DOI Creative Commons
Mette Nyholm Jensen, Ida Marchen Egerod Israelsen, Jonathan H. Wardman

и другие.

Fluids and Barriers of the CNS, Год журнала: 2025, Номер 22(1)

Опубликована: Апрель 24, 2025

Cerebrospinal fluid (CSF) is produced and absorbed at a balanced rate to maintain constant intracranial pressure (ICP). The CSF dynamics are, however, disturbed in several pathological conditions, leading elevated ICP, which may have fatal outcomes if left untreated. Treatment options for these conditions are limited invasive neurosurgery, novel pharmacological approaches manage ICP pathology sought. Here, we aimed demonstrate the potential of glucagon-like peptide-1 receptor (GLP-1R) as such target. We administered male rats with intraperitoneal (i.p.) or intracerebroventricular (i.c.v.) GLP-1R agonist (exendin-4) antagonist (exendin-9-39) followed by vivo determination dynamics. expression CSF-secreting choroid plexus was demonstrated RNAScope situ hybridization western blotting transporter activity radio-isotope flux assays. activation increased secretion an associated elevation whereas inhibition reduced secretion. These effects were observed central, but not peripheral, administration antagonist, suggesting on luminal, CSF-facing side plexus, aligned GLP-1R-mediated modulation luminally-expressed transporters excised plexus. Low level mRNA protein levels. Modulation affects production, suggests that signalling control homeostasis.

Язык: Английский

Процитировано

0
Pulmonary artery pressure trajectories in heart failure patients treated with GLP‐1 receptor agonists DOI Creative Commons
Haoran Jiang, Phuuwadith Wattanachayakul, Veraprapas Kittipibul

и другие.

ESC Heart Failure, Год журнала: 2025, Номер unknown

Опубликована: Апрель 27, 2025

Abstract Aims Data support favourable haemodynamic benefits of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) on improving cardiac structural abnormalities and function in patients with heart failure (HF). However, the direct effects GLP‐1 RAs remain inadequately characterized. We aim to investigate temporal trends pulmonary artery pressure (PAP) HF receiving RAs. Methods results In this single‐centre retrospective cohort study, we identified a CardioMEMS device who received semaglutide or tirzepatide for at least 6 months during monitoring period. Patients were already prior implantation excluded. The relationship between weight change PAPs was assessed using Pearson correlation. A total nine included (54 years, BMI 41.4 kg/m 2 , 67% men, 44% EF < 40%, 89% diabetes, semaglutide). Median dose (or equivalent) 0.9 (range 0.25–1) mg/week. Body significantly decreased from 123.6 117.2 kg ( P = 0.047), while guideline‐directed medical therapy (GDMT) loop diuretic uses dosages remained unchanged. Significant reductions observed systolic PAP (38.9 34.0 mmHg, 0.045), diastolic (20.0 17.8 0.019) mean (27.3 24.3 0.018). There significant correlation loss r 0.69, 0.04) 0.72, 0.029). Conclusions GLP1‐RA use associated body months, despite no changes GDMT doses.

Язык: Английский

Процитировано

0